Human Chorionic Gonadotropin (hCG): Identity, Activity Units, Evidence, and FDA Product Boundaries

hCG is a family-level name, not a complete material specification

Human chorionic gonadotropin is a glycoprotein hormone composed of two noncovalently associated subunits, commonly called alpha and beta. The current PREGNYL record describes a urinary-derived chorionic gonadotropin preparation, while the current OVIDREL record describes recombinant choriogonadotropin alfa produced in Chinese hamster ovary cells.[1][2]

Those records establish that products grouped under the broad hCG name can differ in biological source, manufacturing process, glycosylation, presentation, activity calibration, and application status. A catalog label saying only “HCG” and an International Unit value does not disclose which preparation is present.

This page summarizes identity, measurement, human evidence, and current U.S. regulatory records. It does not provide medical advice or instructions for using any substance.

Identity at a glance

FDA’s substance registry states that the existence of a UNII does not imply regulatory review or approval.[4][5] A substance identifier is not a certificate, batch result, or finished-drug authorization.

Why hCG activity units and mass are not interchangeable

An International Unit is an assigned measure of biological activity relative to a defined reference and assay. A milligram or microgram is a measure of mass. The two quantities answer different questions.

The current OVIDREL label is a useful example because it provides a characterized recombinant identity, an active-ingredient mass, and a biological activity calibration against international reference IS75/587.[2] The current PREGNYL label instead expresses the named finished product’s chorionic-gonadotropin content in USP units and identifies its urinary source.[1]

These product-specific records do not create a universal conversion for an unidentified “HCG” vial. A scientifically complete activity claim needs, at minimum:

• the exact hCG substance and biological source;
• the activity assay and reference preparation;
• the assigned activity and result uncertainty;
• the active-moiety or protein mass, if claimed;
• the formulation and lot to which the result applies.

Evidence label: Official product and assay records for the named finished products. F, unresolved for transfer to any material whose source and activity method are not public.

What human evidence is summarized in the OVIDREL label?

The current OVIDREL label summarizes three well-controlled studies in women: two in assisted reproductive technology programs and one in ovulation induction. These studies compared the named recombinant finished product with approved urinary-derived hCG comparators on protocol-defined endpoints.[2]

The label reports that the tested recombinant masses and the urinary-derived comparator produced comparable or equivalent results on the relevant primary endpoints. This is human evidence for the finished products, populations, and protocols studied. It does not validate every material sold as hCG, establish equivalence across formulations, or identify a commercial research vial.

Evidence tier: B, Human evidence for the narrow named-product comparative propositions in the current label. F, unsupported for transfer to an unverified catalog material.

Negative and null findings

Three limiting findings belong beside any discussion of hCG:

• The OVIDREL program did not establish that the higher tested recombinant mass produced a superior primary outcome. The label describes the tested masses as clinically and statistically equivalent to each other and to the urinary comparator for the relevant primary endpoint.[2]
• The OVIDREL pharmacology section says pharmacodynamic effects were not generally proportional to exposure and, in some cases, appeared near maximal at the lower tested mass.[2]
• The current PREGNYL label states that hCG has no known effect on fat mobilization, appetite, hunger, or body-fat distribution and that there is no substantial evidence it adds weight loss beyond caloric restriction.[1]

These are product-label findings, not a recommendation about use. They directly rule out a “more is better” narrative and an evidence-based weight-loss claim.

Evidence tier: B, Human evidence with a comparative null finding for the OVIDREL program. F, directly contradicted for a general hCG fat-loss or weight-loss claim.

Current U.S. FDA status

PREGNYL is a licensed prescription finished product containing urinary-derived chorionic gonadotropin under BLA 017692.[1] OVIDREL is a licensed prescription finished product containing recombinant choriogonadotropin alfa under BLA 021149.[2][3]

Their approvals are specific to the named products, applications, manufacturing records, formulations, presentations, indications, and current labels. FDA approval does not transfer to:

• the ingredient name hCG by itself;
• an unidentified bulk or research material;
• a product with a similar activity number;
• a product that has not been shown to match PREGNYL or OVIDREL;
• a seller’s claim of “research grade,” purity, testing, or equivalence.

No cited source establishes that a Serum Research catalog item is PREGNYL, OVIDREL, a generic, a biosimilar, or clinically equivalent to either finished product.

Status checked: August 27, 2026.

Important evidence limitations

• Endogenous hCG, urinary-derived preparations, and recombinant choriogonadotropin alfa should not be collapsed into one undifferentiated commercial identity.
• Glycoprotein source and glycosylation can matter; nominal IU alone does not describe either.
• Activity units do not reveal protein mass, glycoform distribution, excipients, impurities, aggregation, or lot identity.
• A named-product trial cannot verify a material it did not test.
• Human evidence in defined reproductive-medicine programs does not support unrelated weight-loss, athletic, recovery, wellness, or performance claims.
• This page does not evaluate an individual product’s identity, purity, sterility, stability, or suitability.

Frequently asked questions

Is hCG a peptide?

hCG is more accurately described as a glycoprotein hormone composed of alpha and beta subunits. Calling it simply a peptide omits its heterodimeric and glycosylated nature.[1][2]

Are urinary hCG and recombinant hCG identical products?

No. PREGNYL and OVIDREL have different biological sources and manufacturing records, and OVIDREL uses the specific active-ingredient name choriogonadotropin alfa.[1][2] Their shared biological relationship does not make the finished products interchangeable or prove the identity of another material.

Does an hCG value in IU reveal how many milligrams are present?

No. IU express calibrated biological activity; milligrams express mass. A conversion is meaningful only when it is tied to the exact preparation, assay, reference, and characterized product.

Does a higher activity or mass automatically produce a larger effect?

The cited OVIDREL record does not support that inference. Its comparative program reported equivalent primary outcomes across the tested recombinant masses, and the label says pharmacodynamic effects were not generally proportional to exposure.[2]

Does hCG have an established weight-loss effect?

The current PREGNYL label expressly says no known fat-mobilization, appetite, hunger, or body-fat-distribution effect is established and no substantial evidence shows additional weight loss beyond caloric restriction.[1]

Does an FDA UNII mean a substance is approved?

No. FDA’s GSRS pages state that UNII availability does not imply regulatory review or approval.[4][5] Approval belongs to a named finished product and application.

Does this page provide instructions for hCG use?

No. It is an identity, evidence, and regulatory summary and intentionally excludes dosing, administration, reconstitution, and treatment guidance.

Related research-library reading

• Menotropins (hMG): Mixture Identity, Activity Units, Human Evidence, and FDA Product Boundary
• How We Review Evidence
• Quality Testing: What Identity, Assay, and Purity Results Can and Cannot Show
• Certificates and Lot-Specific Records

Do not place product cards or commercial calls to action inside this evidence discussion.

Sources

1. DailyMed: current PREGNYL label, urinary source, glycoprotein/subunit description, USP activity units, current product labeling, and explicit weight-loss limitation.
2. DailyMed: current OVIDREL label, recombinant identity, Chinese hamster ovary source, glycosylated subunits, mass and activity calibration, and comparative human studies.
3. FDA Purple Book: OVIDREL, BLA 021149, licensed product, application, and presentation.
4. FDA GSRS: chorionic gonadotropin, UNII 20ED16GHEB, substance identity and approval disclaimer.
5. FDA GSRS: choriogonadotropin alfa, UNII 6413W06WR3, recombinant substance identity and approval disclaimer.
6. FDA: Approved Drugs, Questions and Answers, product-specific meaning of FDA approval.